Bluejay Diagnostics jumps as FDA agrees on device approval pathway

Bluejay Diagnostics

09/06/2022 13:10

** Shares of Bluejay Diagnostics Inc  BJDX.O  up 32.6% at
$1.71 premarket 
    ** U.S. FDA says co's test for detecting a biomarker tied to
infection, inflammation and cancer can be considered under its
"De Novo" approval pathway  urn:newsml:reuters.com:*:nGNX9zFFSZ
    ** The pathway is used by the FDA for novel medical devices
that do not have any other similar devices to compare with 
    ** BJDX shares have fallen ~75% since IPO in November last
year 

 (Reporting by Manas Mishra)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15))